Physician profile
Chad A Hogan
NPI 1235187279
$1,823.15
in general payments reported to CMS, 2019-2025
22 companies · $630 in 2025
The $630 reported for 2025 was more than what 78% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $78.82 · 2022: $60.22 · 2023: $384 · 2024: $669 · 2025: $630.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,684.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,684.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $256.14 | 2022-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $252.99 | 2019-2025 | Kisunla, Mounjaro, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $194.44 | 2023-2025 | |
| Astellas Pharma US INC | $187.09 | 2023-2024 | Veozah |
| E.R. Squibb & Sons, L.L.C. | $124.72 | 2023 | Camzyos |
| Pfizer INC. | $120.78 | 2023-2025 | |
| Novo Nordisk INC | $114.80 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Cvrx, INC. | $112.40 | 2024 | Barostim Neo System |
| Exact Sciences Corporation | $96.17 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Amgen INC. | $69.63 | 2023-2025 | Repatha, Otezla, Repatha |
| Abbvie INC. | $62.44 | 2023-2024 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $45.04 | 2022 | |
| Merck Sharp & Dohme LLC | $31.32 | 2023-2024 | Belsomra, Gardasil, Gardasil 9 |
| Eisai INC. | $29.38 | 2025 | |
| Dexcom, INC. | $19.57 | 2025 | Dexcom G6 Transmitter |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dynavax Technologies Corporation | $18.72 | 2025 | Heplisav-B |
| Seqirus USA INC | $18.70 | 2024 | Flucelvax, Fluad |
| Esperion Therapeutics, INC. | $15.84 | 2025 | Nexletol |
| Hikma Pharmaceuticals USA | $14.68 | 2024 | Ryaltris |
| Mylan Specialty L.P. | $13.71 | 2019 | |
| Supernus Pharmaceuticals, INC. | $13.10 | 2023 | Qelbree |
| Janssen Pharmaceuticals, INC | $11.49 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chad Hogan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.